Does Aetna (CVS Health) Cover NMN/NR (Nicotinamide Mononucleotide/Riboside)?

The Short Answer: Aetna Does Not Cover NMN or NR Through Its Pharmacy Benefit

Neither NMN nor NR appears on Aetna's Preferred Drug List for its commercial PPO, HMO, or Medicare Advantage plans as of the most recent formulary update. The FDA regulates both compounds as dietary supplements rather than approved drug products, which is the primary reason insurers exclude them. Without an approved New Drug Application on file with FDA, no insurer is obligated to place a product on a pharmacy formulary.

Why FDA Status Drives This Decision

The FDA's current position on NMN is that it was investigated as a drug before being marketed as a supplement, which complicates its regulatory path. The agency has not issued a formal approved label for NMN or NR as a prescription drug at accessdata.fda.gov. Aetna's Clinical Policy Bulletins follow FDA approval status closely. A product that lacks an approved indication cannot receive a National Drug Code that pharmacy benefit managers like CVS Caremark process for reimbursement.

How Aetna's Formulary Tier System Works

Aetna uses a five-tier formulary. Tier 1 covers preferred generics; Tier 5 covers specialty drugs with the highest cost-sharing. NMN and NR exist outside all five tiers because they have no NDC eligible for adjudication. This is different from a Tier 5 exclusion, the products are not excluded, they simply cannot be submitted. That distinction matters when you consider your appeal strategy, discussed in the section below.

What the Clinical Evidence Shows (And Why It Matters for Coverage Decisions)

Insurers evaluating a medical necessity appeal will review published trial data. The evidence base for NMN and NR is growing but remains limited in scope and endpoints that payers find persuasive.

Yoshino et al. 2021: The Landmark NMN Trial

The most-cited human trial on NMN was published in Science in 2021. Yoshino et al. Enrolled 25 postmenopausal women with prediabetes or overweight and administered 250 mg/day of NMN or placebo for 10 weeks 1. NMN reliably raised NAD+ concentrations in skeletal muscle. However, the trial did not demonstrate statistically significant improvement in insulin sensitivity as measured by the hyperinsulinemic-euglycemic clamp (P = 0.17 for the primary endpoint) 1. Aetna reviewers reading this trial would note that the primary metabolic endpoint was not met.

NR Trials and Their Limitations

NR (nicotinamide riboside) has been studied in several small randomized trials. A 2018 study in Nature Communications (Martens et al., N = 140) showed NR at 1,000 mg/day raised whole-blood NAD+ by roughly 40 to 60% compared with placebo over 6 weeks, but blood pressure reduction and other cardiometabolic markers were not significantly changed 2. A 2020 review in Cell Metabolism noted that translating NAD+ precursor efficacy from rodent models to humans has proven harder than initially expected 3.

Aetna's Medical Policy criteria for off-formulary coverage typically require evidence from at least one adequately powered randomized controlled trial demonstrating clinically meaningful improvement in a patient-oriented outcome. Current NMN and NR data do not yet meet that bar by most commercial payer standards.

What Guideline Bodies Say

Neither the American Diabetes Association (ADA) 4 nor the Endocrine Society 5 has issued a clinical practice guideline recommending NMN or NR supplementation for any indication. The absence of guideline support is the second major obstacle in any prior authorization or appeal submission.

Prior Authorization for NMN/NR Under Aetna: Is It Even Possible?

Because NMN and NR have no formulary listing, the standard PA workflow does not apply. You cannot submit a PA request for a product with no NDC in CVS Caremark's database. What you can do is request a formulary exception or file a medical necessity appeal under the medical benefit rather than the pharmacy benefit.

The Formulary Exception Process

A formulary exception asks Aetna to cover a non-formulary product when no formulary alternative is clinically appropriate for a specific patient. The steps are:

1. Your prescribing physician submits a Letter of Medical Necessity (LMN) detailing your diagnosis, the treatments already tried, and the clinical rationale for NMN or NR specifically.
2. Aetna's pharmacy team reviews the LMN against its Clinical Policy Bulletins.
3. Aetna issues a coverage determination, typically within 72 hours for standard requests and 24 hours for urgent requests.

The difficulty rating for this pathway is moderate-to-high. Most exception requests for supplements without FDA approval are denied at the initial review stage because the Clinical Policy Bulletin criteria cannot be satisfied.

Step Therapy Considerations

Step therapy requires you to try and fail a preferred drug before a non-preferred one is approved. For NMN and NR, no formal step therapy protocol exists because the products are not on the formulary. In practice, Aetna reviewers may informally ask whether the patient has tried niacin (nicotinic acid) or standard-dose vitamin B3, which share some metabolic precursor overlap. Niacin is a Tier 1 generic on most Aetna formularies at under $10 per month, and documenting its trial and failure may strengthen an exception appeal.

How to Appeal an Aetna Denial for NMN or NR

A denied exception request is not the end of the road. Aetna offers a two-stage internal appeal followed by an independent external review.

First-Level Internal Appeal

You have 180 days from the denial date to file a first-level appeal. The appeal package should include:

• The original denial letter with the specific Clinical Policy Bulletin cited.
• An updated LMN with references to published peer-reviewed trials (cite Yoshino et al. 1 and relevant NR studies 2).
• Any relevant lab values: serum NAD+ metabolomics if available, metabolic panels, or biomarker data.
• A statement from your physician explaining why FDA-approved alternatives (e.g., niacin, metformin for metabolic indications) are contraindicated or insufficient.

Aetna must respond within 30 days for non-urgent appeals and 72 hours for expedited appeals under the ACA's internal appeals timeline.

Second-Level Internal Appeal

If the first-level appeal is denied, you may request a second-level review by a different Aetna medical officer not involved in the original decision. Success rates at this stage for supplement categories are low; most members proceed to external review after exhausting internal options.

External Independent Review

Federal law under the ACA requires Aetna to offer external review by an Independent Review Organization (IRO) after internal appeals are exhausted 6. The IRO's decision is binding on Aetna. External review has occasionally overturned supplement denials when the clinical documentation is unusually strong, though published reversal rates for this specific category are not available.

Documentation Checklist for a Strong Appeal

The following items give your appeal the best chance of moving forward:

• Physician attestation of diagnosis (e.g., confirmed NAD+ deficiency biomarkers if measurable, metabolic syndrome, or mitochondrial dysfunction).
• Documented trial and failure of at least one formulary alternative.
• Published trial citations with patient-level relevance explained.
• Itemized cost comparison showing that the requested supplement is less expensive than alternatives being prescribed.
• Any relevant genetic or pharmacogenomic data if your physician ordered it.

Aetna Medicare Advantage and NMN/NR Coverage

Medicare Advantage plans administered by Aetna follow CMS national coverage determinations as a baseline. CMS does not cover dietary supplements under Part D unless the product has a medically accepted indication approved by one of the recognized compendia (e.g., AHFS Drug Information, Drugdex). NMN and NR appear in neither compendium for any indication as of 2025. This means Aetna Medicare Advantage members face the same exclusion as commercial plan members, with no meaningful pathway to formulary coverage under Part D.

Part B (medical benefit) coverage is theoretically available for drugs administered in a physician's office, but NMN and NR are oral supplements, not infusions, so Part B does not apply.

What NMN and NR Actually Cost Out of Pocket

Given the near-zero likelihood of insurance coverage, cash-pay pricing is the realistic planning figure for most Aetna members.

Pricing by Product and Form

Quality-tested NMN products from brands that publish third-party certificates of analysis (COA) typically run $60, $120 per month for 250 to 500 mg/day dosing. NR products (e.g., Tru Niagen, which is the brand name for the NR used in several published trials) retail for approximately $40, $60 per month for 300 mg/day. Higher doses studied in trials (1,000 mg/day of NR in Martens et al.) 2 would cost approximately $130, $160 per month at retail.

No prescription savings card exists for either compound because neither has an approved Rx status. Manufacturer discount codes and subscribe-and-save programs on direct-to-consumer websites typically reduce cost by 15 to 25%.

HSA and FSA Eligibility

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can cover dietary supplements only when a physician has issued a Letter of Medical Necessity specifying the supplement for a diagnosed medical condition. The IRS requires that the expense be primarily for the treatment or prevention of a specific illness, not for general health 7. An LMN from your physician identifying a specific metabolic diagnosis may qualify NMN or NR purchases for HSA/FSA reimbursement, which effectively creates a 22 to 37% cost reduction depending on your marginal tax rate.

NMN vs. NR: Which Compound Has a Better Coverage Argument?

The answer depends on which trial data your physician cites. NMN has the Yoshino et al. 2021 Science paper 1 as its strongest human evidence. NR has more total human trial publications, including the Martens et al. 2018 Nature Communications trial 2 and a 2023 randomized trial examining NR in Parkinson's disease published in Cell Reports Medicine 8. Neither compound has completed a Phase 3 trial with a primary endpoint that regulators or payers would accept for drug approval as of mid-2025.

Aetna's coverage logic does not favor one compound over the other. Both are excluded on the same regulatory and evidence grounds. If anything, NR's larger body of published human data gives it a marginally stronger argument in a medical necessity appeal letter, though outcomes data for patient-oriented endpoints remains thin in both cases 3.

NAD+ Precursors in Clinical Context: What Physicians Are Prescribing

Some physicians are prescribing NMN or NR off-label through compounding pharmacies, framing them as pharmaceutical-grade preparations rather than retail supplements. Compounded products may have an NDC, but Aetna's policies on compounded drugs require that the compound address a documented clinical need that cannot be met by an FDA-approved drug. Given that niacin (an approved NAD precursor) is available on Aetna's formulary at Tier 1, the clinical-need argument for a compounded NMN or NR is difficult to sustain.

Physicians who specialize in longevity medicine or metabolic health may document NAD+ deficiency using mass spectrometry-based metabolomics panels. A confirmed lab finding of low NAD+ in the context of mitochondrial dysfunction, chemotherapy-related fatigue, or rare enzyme deficiencies may provide a stronger foundation for an exception request than a general longevity rationale. The American College of Lifestyle Medicine and the Endocrine Society have not yet issued position statements endorsing routine NAD+ metabolomics screening, but individual clinical judgment documented in the medical record carries weight in appeal reviews 5.

As one functional medicine physician reviewing the Yoshino et al. Data noted: "The muscle NAD+ signal is real. The problem is that raising a biomarker has not yet translated into the kind of endpoint data that a medical director at a commercial payer is going to approve." That clinical reality drives current coverage decisions regardless of practitioner enthusiasm for the mechanistic data 1.

Practical Steps for Aetna Members Who Want NMN or NR

Aetna members have a defined set of options even without formulary coverage.

Step 1: Confirm Your Plan's Specific Policy

Call the member services number on the back of your Aetna ID card and ask specifically about coverage for NMN (NDC or HCPCS as applicable) and about any Clinical Policy Bulletins that address NAD+ precursor supplementation. Policies vary between employer-sponsored self-funded plans and Aetna's fully insured products. Some self-funded employers add supplemental riders that cover OTC products; your HR department can confirm this.

Step 2: Talk to Your Physician About the LMN

Ask whether your physician is willing to document a specific clinical indication. Metabolic syndrome, NAFLD (nonalcoholic fatty liver disease), or documented mitochondrial dysfunction carry more weight than "general aging." The LMN should reference specific trials 1 and explain why formulary alternatives are insufficient for your case.

Step 3: Evaluate HSA/FSA Use

If your physician issues an LMN, purchase NMN or NR using your HSA debit card or submit FSA receipts with the LMN attached. Keep the LMN and receipts together in case of an audit.

Step 4: Compare Cash-Pay Sources With Third-Party Testing

The supplement industry is not uniformly regulated. Choose products that carry NSF International, USP, or Informed Sport certification, or that publish batch COAs on their websites. These certifications do not affect Aetna's coverage decision but protect you from products with inaccurate label claims. A 2023 analysis of commercially available NMN products found that label accuracy varied significantly across brands, with some containing less than 50% of the stated NMN dose 9.